Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophi…
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Solid Biosciences Inc.'s gradings, price targets and earnings estimates. None
Reported
Past Estimate Consensus
Future Estimate Consensus
Solid Biosciences Inc. can't present any analysts estimates at the moment detail analysis.